Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Amy Jackson to Leave PhRMA Japan, Kawabata to Take Up Interim Role
October 6, 2021
- 1,749 Generic Products Now under Supply Restrictions: JGA
October 5, 2021
- Think Twice before Issuing Long-Term Prescriptions for Supply-Curbed Generics: JMA
October 5, 2021
- MEJ Study Group Calls for Electronic Medical Chart Reform to Expedite Clinical Trials, New Drug Development
October 4, 2021
- FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
- FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
- Generic Use Rate Slips to 79.8% in April-June: JGA
September 30, 2021
- Chuikyo Payer Rep Wants to Cut into Cost-Based Method, Adjustment Rate, Off-Year Revision in FY2022 Reform, Eyes Special Rules for Aducanumab
September 27, 2021
- Teva Takeda CEO Named Chairman of Established Drugs’ Group
September 24, 2021
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- FPMAJ Conducting Survey on Efforts for Stable Supplies of Ethical Drugs; Response Deadline Sept. 30
September 21, 2021
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
- Bills Exceeding 10 Million Yen Monthly Increase 60%, SMA Dominates Top 7: Payer Report
September 17, 2021
- JMA Think Tank Sees Problems with Proposals to Revise Health Coverage for Drugs
September 15, 2021
- Generic Trade Group Sets Out 4 Pledges on Quality, Stable Supply
September 15, 2021
- FPMAJ Vows to Work towards Achieving New Pharma Industry Vision
September 15, 2021
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- JMA Think Tank Urges Discussions to Prep for Aducanumab Approval
September 8, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…